News
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...
Hims & Hers Health, Inc.'s subscriber growth, Novo Nordisk partnership, and FDA pill approval could boost financials. Click ...
Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.
Hims & Hers Health (NYSE: HIMS) stock surged 23% on Tuesday, April 29, after Novo Nordisk announced plans to offer popular ...
Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...
Palantir Technologies shares are down nearly 8% after the software group's stellar earnings could not prevent some profit taking after the stock's strong rally to near record highs.
Hims & Hers stock was trading lower but has since reversed and began trading higher after the company reported first-quarter ...
Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...
Hims & Hers Health (HIMS) stock is getting attention from options bulls after beating first-quarter expectations ...
Hims & Hers Health (HIMS) stock declined about 2% yesterday. The fall came after the U.S. Food and Drug Administration (FDA) ...
Stocktwits on MSN12h
Hims & Hers Stock Slides Pre-Market As Q2 Sales View Misses Estimates, But Retail Traders Shrug It OffTelehealth firm Hims & Hers Health Inc. (HIMS) reported strong first-quarter 2025 results, with revenue more than doubling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback